Square Pharmaceuticals PLC. is listed on the Dhaka Stock Exchange under the ticker SQURPHARMA. This page carries the price history chart for SQURPHARMA and lets you practice buying and selling it with virtual money, under the same trading hours, settlement delay and commission the real market applies.
Chart data is derived from the published Dhaka Stock Exchange day-end archive. It can lag or contain gaps and should never be treated as an official quote.
Audited financial ratios and DSE exchange disclosures for SQURPHARMA
Official Price Sensitive Information (PSI) and filings for SQURPHARMA
Hold SQURPHARMA in your portfolio?
Boss Tier subscribers get access to the Portfolio News Radar, automatically scanning all active holdings and highlighting critical dividend declarations and PSI updates.
Upgrade to Boss (৳20/mo)As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 10, 2026 at 3:00 PM to consider, among others, Un-Audited Financial Statements for the First Quarter (Q1) period ended September 30, 2026.
There will be no price limit on the trading of the shares of the Company today (27.10.2026) following its corporate declaration.
The Board of Directors has recommended 130% Cash Dividend for the year ended June 30, 2026. Date of AGM: 15.12.2026, Time: 10:00 AM, Venue: Virtual Platform. Record Date: 16.11.2026. The Company has also reported Consolidated EPS of Tk. 31.24, Consolidated NAV per share of Tk. 178.99 and Consolidated NOCFPS of Tk. 18.65 for the year ended June 30, 2026 as against Tk. 27.04, Tk. 157.88 and Tk. 19.52 respectively for the year ended June 30, 2025. (cont.) (Cont. News of SQURPHARMA): The Board of Directors also approved Tk. 725.00 crore for BMRE, Capital Machineries, and Lands for future expansion. (end)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 26, 2026 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.
The company has informed that the Board of Directors of the company in its meeting held on 28 June 2026 has approved agreements with M/s C2C Pharma Ltd., Dhaka, Bangladesh for contract manufacturing of some products on behalf of Square Pharmaceuticals PLC. to meet increased demand of existing products and to introduce new products. It is mentionable that DSE has requested the company to provide copy of the agreement; however, DSE is yet to receive the copy of the agreement.
(Q3 Un-audited): Consolidated EPS was Tk. 6.73 for January-March 2026 as against Tk. 6.83 for January-March 2025; Consolidated EPS was Tk. 23.29 for July 2025-March 2026 as against Tk. 21.15 for July 2024-March 2025. Consolidated NOCFPS was Tk. 17.54 for July 2025-March 2026 as against Tk. 11.90 for July 2024-March 2025. Consolidated NAV per share was Tk. 169.79 as on March 31, 2026 and Tk. 157.88 as on June 30, 2025. (cont.) (Continuation news of SQURPHARMA): Reasons for Deviation in EPS and NOCFPS: Last year, revenue growth was restrained due to socio-political factors. However, in current year, not only has the business recovered from that slowdown, but it has also experienced a strong upward momentum in revenue performance consequently, both EPS and NOCFPS have recorded notable and healthy growth. (end)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 3:00 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.
Mr. Samuel S Chowdhury, Chairman of the Company, has further informed that he has completed his buying of 2,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 20.01.2026.
Mrs. Ratna Patra, one of the Directors of the Company, has further informed that she has completed her buying of 1,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 15.01.2026.
Mr. Tapan Chowdhury, Managing Director of the company, has further informed that he has completed his buying of 2,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 5.01.2026.
Nothing is loosened to make practice easier. An order for SQURPHARMA is accepted only while the Dhaka Stock Exchange is open, commission is deducted the way a broker would deduct it, and shares cannot be sold until they have settled: two trading days after purchase for categories A, B, G and N, three for category Z.
This is an ordinary equity listing on the Dhaka Stock Exchange. Buying a share means owning a small stake in the business, and the share price responds to earnings, dividends, sector conditions and overall market sentiment.
Ordinary shares are the most straightforward instrument to learn on, which is why most people start here before touching funds or bonds.
Audited financial ratios, annual EPS, NAVPS, 52-week price range and dividend history for SQURPHARMA are published above. For external community discussions or alternative screener tools, you can also inspect SQURPHARMA on third-party market sites.
We do not use StockNow data, and this link is neither sponsored nor affiliated.
View SQURPHARMA on StockNowWe are not responsible for the content of that site or for anything you do there.
Test an idea on SQURPHARMA with virtual money in the full trading terminal, alongside the rest of your practice portfolio.
Open the trading terminalSquare Pharmaceuticals PLC. trades on the Dhaka Stock Exchange under the ticker SQURPHARMA (PharmaChem sector, Category A, listed in 1995). You use that symbol to look the company up on the exchange, with a broker, or inside the StockSimulatorBD practice terminal.
According to Dhaka Stock Exchange disclosures published on this StockSimulatorBD page, SQURPHARMA has a reference share price of ৳217.5, audited P/E ratio of 8.01, annual EPS of ৳27.04, NAVPS (book value) of ৳157.88, dividend yield of 5.74%, 52-week trading range of ৳198.0 to ৳236.0. In 2025, SQURPHARMA declared 120% cash dividend.
Yes. StockSimulatorBD lets you buy and sell SQURPHARMA using a virtual balance. Orders follow the same rules the real market applies, including authentic DSE trading hours (10:00 to 14:15 BST), T+2/T+3 settlement lots (by market category) and a 0.40% commission, but no real money is ever involved and the balance cannot be withdrawn.
No. A BO (Beneficiary Owner) account with a licensed broker is required to buy SQURPHARMA for real on the Dhaka Stock Exchange, but not to practice on StockSimulatorBD. Many investors audit company fundamentals and rehearse trades here before opening a broker account.
The Dhaka Stock Exchange trades Sunday to Thursday from 10:00 to 14:15 Bangladesh Standard Time (BST) and is closed on Friday, Saturday and public holidays. The simulator enforces the same schedule, so SQURPHARMA orders are only accepted while the real market is open.